Association of peroxisome proliferator-activated receptors/retinoic acid receptors with renal diseases

Journal of Receptors and Signal Transduction

Volumn 33, Issue 6, 2013, Pages 349-352

  Zhou, Tian Biao ^a,b   Drummen, Gregor P C ^c   Jiang, Zong Pei ^a   Long, Yao Bin ^b   Qin, Yuan Han ^b  

^a THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^c BioandNano Solutions   (Germany)

Author keywords

Peroxisome proliferator activated receptor ; Renal diseases; Retinoic acid; Retinoic acid receptors

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RETINOIC ACID RECEPTOR;

CELL PROLIFERATION; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DNA POLYMORPHISM; GLOMERULOSCLEROSIS; HUMAN; HYPERLIPIDEMIA; IMMUNOGLOBULIN A NEPHROPATHY; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; KIDNEY DISEASES; PPAR GAMMA; RECEPTORS, RETINOIC ACID; TRANSCRIPTION, GENETIC;

EID: 84890224276     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2013.838786     Document Type: Review

References (51)

1. Lamers C, Schubert-Zsilavecz M, Merk D. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present). Expert Opin Ther Pat 2012;22:803-41.
2. Fucci A, Colangelo T, Votino C, et al. The role of peroxisome proliferator-activated receptors in the esophageal, gastric, and colorectal cancer. PPAR Res 2012;2012:242498.
3. Mandard S, Patsouris D. Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors. PPAR Res 2013;2013:613864.
4. Tsukahara T, Haniu H, Matsuda Y. PTB-associated splicing factor (PSF) is a PPARgamma-binding protein and growth regulator of colon cancer cells. PLoS One 2013;8:e58749.
5. Takada I, Yogiashi Y, Kato S. Signaling crosstalk between PPARgamma and BMP2 in mesenchymal stem cells. PPAR Res 2012;2012:607141.
6. Ramirez A, Ballard EN, Roman J. TGFbeta1 controls PPARgamma expression, transcriptional potential, and activity, in part, through smad3 signaling in murine lung fibroblasts. PPAR Res 2012;2012: 375876.
7. Duong V, Rochette-Egly C. The molecular physiology of nuclear retinoic acid receptors. From health to disease. Biochim Biophys Acta 2011;1812:1023-31.
8. Long YB, Qin YH, Zhou TB, Lei FY. Association of retinoic acid receptors with extracellular matrix accumulation in rats with renal interstitial fibrosis disease. Int J Mol Sci 2012;13:14073-85.
9. Hauksdottir H, Farboud B, Privalsky ML. Retinoic acid receptors beta and gamma do not repress, but instead activate target gene transcription in both the absence and presence of hormone ligand. Mol Endocrinol 2003;17:373-85.
10. He BC, Chen L, Zuo GW, et al. Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 2010;16:2235-45.
11. Yang J, Zhou Y, Guan Y. PPARgamma as a therapeutic target in diabetic nephropathy and other renal diseases. Curr Opin Nephrol Hypertens 2012;21:97-105.
12. Kim MK, Ko SH, Baek KH, et al. Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes. Korean J Intern Med 2009;24:227-32.
13. Pistrosch F, Passauer J, Herbrig K, et al. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy. Horm Metab Res 2012;44:914-18.
14. Tang SC, Leung JC, Chan LY, et al. Renoprotection by rosiglitazone in accelerated type 2 diabetic nephropathy: role of STAT1 inhibition and nephrin restoration. Am J Nephrol 2010;32: 145-55.
15. Chodavarapu H, Grobe N, Somineni HK, et al. Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. PLoS One 2013;8: e62833.
16. Bilan VP, Salah EM, Bastacky S, et al. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. J Endocrinol 2011;210:293-308.
17. Zhang H, Zhu S, Chen J, et al. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care 2012;35:1388-93.
18. Zhou XJ, Cheng FJ, Qi YY, et al. FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy. PLoS One 2013; 8:e61208.
19. Song J, Sakatsume M, Narita I, et al. Peroxisome proliferatoractivated receptor gamma C161T polymorphisms and survival of Japanese patients with immunoglobulin A nephropathy. Clin Genet 2003;64:398-403.
20. Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor gamma C161!T polymorphism and coronary artery disease. Cardiovasc Res 1999;44:588-94.
21. Xiao J, Leung JC, Chan LY, et al. Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy. Nephrol Dial Transplant 2009;24:2067-77.
22. Lai KN, Chan LY, Guo H, et al. Additive effect of PPAR-gamma agonist and ARB in treatment of experimental IgA nephropathy. Pediatr Nephrol 2011;26:257-66.
23. Collino M, Patel NS, Lawrence KM, et al. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int 2005;68: 529-36.
24. Betz B, Schneider R, Kress T, et al. Rosiglitazone affects nitric oxide synthases and improves renal outcome in a rat model of severe ischemia/reperfusion injury. PPAR Res 2012;2012:219319.
25. Reel B, Guzeloglu M, Bagriyanik A, et al. The effects of PPARgamma agonist pioglitazone on renal ischemia/reperfusion injury in rats. J Surg Res 2013;182:176-84.
26. Zhu C, Huang S, Yuan Y, et al. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARgamma. Am J Pathol 2011;178:2020-31.
27. Yuan Y, Zhang A, Huang S, et al. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROSdependent EGFR intracellular signaling. Am J Physiol Renal Physiol 2011;300:F393-402.
28. Zou R, Xu G, Liu XC, et al. PPARgamma agonists inhibit TGFbeta- PKA signaling in glomerulosclerosis. Acta Pharmacol Sin 2010;31:43-50.
29. Calkin AC, Giunti S, Jandeleit-Dahm KA, et al. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 2006;21: 2399-405.
30. Zhou TB, Ou C, Luo CP, Xu HL. Protective effects of PPARgamma agonist in glomerulosclerosis rats induced by adriamycin. Ren Fail 2012;34:940-1.
31. Yoshihara D, Kurahashi H, Morita M, et al. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 2011;300:F465-74.
32. Lin Q, Gu Y, Ma J, Lin SY. Protection of rosiglitazone against renal interstitial lesion and its mechanism. Zhonghua Yi Xue Za Zhi 2005;85:1618-24.
33. Chung BH, Li C, Sun BK, et al. Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. Am J Transplant 2005;5:1856-67.
34. Duester G. Retinoic acid synthesis and signaling during early organogenesis. Cell 2008;134:921-31.
35. Kam RK, Deng Y, Chen Y, Zhao H. Retinoic acid synthesis and functions in early embryonic development. Cell Biosci 2012;2:11.
36. Marletaz F, Holland LZ, Laudet V, Schubert M. Retinoic acid signaling and the evolution of chordates. Int J Biol Sci 2006;2: 38-47.
37. Noy N. Between death and survival: retinoic acid in regulation of apoptosis. Annu Rev Nutr 2010;30:201-17.
38. Zhou TB, Drummen GP, Qin YH. The controversial role of retinoic Acid in fibrotic diseases: analysis of involved signaling pathways. Int J Mol Sci 2012;14:226-43.
39. Ratnam KK, Feng X, Chuang PY, et al. Role of the retinoic acid receptor-alpha in HIV-associated nephropathy. Kidney Int 2011;79: 624-34.
40. Zhong Y, Wu Y, Liu R, et al. Novel retinoic acid receptor alpha agonists for treatment of kidney disease. PLoS One 2011;6:e27945.
41. Schaier M, Liebler S, Schade K, et al. Retinoic acid receptor alpha and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat. J Mol Med (Berl) 2004;82:116-25.
42. He JC, Lu TC, Fleet M, et al. Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol 2007;18:93-102.
43. Zhou TB. Signaling pathways of PAX2 and its role in renal interstitial fibrosis and glomerulosclerosis. J Recept Signal Transduct Res 2012;32:298-303.
44. Zhou TB. Signaling pathways of apoE and its role of gene expression in glomerulus diseases. J Recept Signal Transduct Res 2013;33:73-8.
45. Zhou TB, Qin YH. The signaling pathways of LMX1B and its role in glomerulosclerosis. J Recept Signal Transduct Res 2012;32: 285-9.
46. Zhou TB, Qin YH. The potential mechanism for the different expressions of gelatinases induced by all-trans retinoic acid in different cells. J Recept Signal Transduct Res 2012;32:129-33.
47. Zhou TB, Qin YH. Signaling pathways of prohibitin and its role in diseases. J Recept Signal Transduct Res 2013;33:28-36.
48. Tabe Y, Konopleva M, Andreeff M, Ohsaka A. Effects of PPARgamma ligands on leukemia. PPAR Res 2012;2012:483656.
49. Kamel-Reid S, Zhang T, Wells RA. Expression of NPM-RARalpha fusion gene in hematopoietic cells confers sensitivity to troglitazone- induced apoptosis. Oncogene 2003;22:6424-35.
50. Tabe Y, Konopleva M, Kondo Y, et al. PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL. Cancer Biol Ther 2007;6:1967-77.
51. James SY, Lin F, Kolluri SK, et al. Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells. Cancer Res 2003;63:3531-8.